An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155 in Healthy Adult Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01077505
• Other study ID #: 107032
• Status: Completed
• Phase: Phase 1
• First received: February 25, 2010
• Last updated: June 13, 2017
• Start date: March 15, 2010
• Est. completion date: November 24, 2010

Study information

• Verified date: June 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.

Description:

This study will be an open-label study in at least one center to evaluate the effect of albiglutide administration on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: November 24, 2010
• Est. primary completion date: November 24, 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy female subjects, defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, clinical laboratory tests, and 12-lead ECG;

• Women of childbearing potential must use protocol-defined contraceptive methods;

• BMI is 19 to 30 kg/m2 and body weight =50 kg (110 lbs) and <114 kg (<250 lbs);

• Aspartate aminotransferase (AST), ALT, alkaline phosphatase, and bilirubin is </=1.5 × ULN;

Exclusion Criteria:

• Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, or ECG;

• Blood pressure =140/90 mm Hg or heart rate >100 beats/minute at Screening;

• Corrected QT (QTc) intervals >450 msec (per ECG machine interpretation);

• Pregnant or nursing females;

• A positive prestudy hepatitis B surface antigen, positive hepatitis C antibody, or HIV result within 3 months of Screening;

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones);

• Smoking or using any nicotine products, including smoking cessation patches containing any amount of nicotine within the 6 months before Screening;

• Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception;

• Subjects have participated in a clinical trial and have received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer);

• History of substance abuse within the past year as determined by the investigator;

• History of alcohol abuse defined as an average weekly intake of >7 drinks;

• Positive urine drug screen at Screening or predose during the Run-in Period and on Day 1 of Periods 1 and 2;

• Use of prescription or nonprescription drugs, vitamins, dietary/herbal supplements including St. John's Wort, nonsteroidal antiinflammatory medications, and aspirin within 14 days or 5 half-lives, whichever is longer prior to the first dose of investigational product;

• Willing to refrain from consuming grapefruit or cranberry products (such as juice, fruit, or nutritional supplements) at any time during participation in the study;

• Donation of blood in excess of 500 mL within 56 days prior to dosing or intention of donating in the month after completing the study;

• History of thyroid dysfunction or an abnormal (i.e., outside normal reference range) thyroid function test assessed by thyroid stimulating hormone (TSH) at Screening;

• History of drug allergy or other allergy, which, in the opinion of the responsible study physician, contradicts the subject's participation;

• History of any condition that would contraindicate OC administration (including hypertension, stroke, ischemic heart disease, venous thromboembolism, carcinoma of the breast, etc.);

• History of type 1 or 2 diabetes mellitus;

• History of migraine if aged >35 years or has focal symptoms associated with migraine;

• Any condition that would affect drug transit time or absorption (e.g., gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's disease, ulcerative colitis, or celiac sprue); or

• Previous or current receipt of exenatide or any other GLP 1 agonist;

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Biological:
• albiglutide
albiglutide 50mg weekly subcutaneous injection

Drug:
• Oral contraceptive (Brevicon)
Oral contraceptive (Brevicon)

Locations

Country	Name	City	State
United States	GSK Investigational Site	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012 Nov;124(6):55-72. doi: 10.3810/pgm.2012.11.2613. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC0-24 of norethindrone and ethinyl estradiol after OC alone in Period 1 and after OC with albiglutide in Period 2.		Day 21
Secondary	Cmax, Cmin, tmax, and t½ of norethindrone and ethinyl estradiol after OC alone on Day 21 of Period 1 and after OC with albiglutide on Day 21 of Period 2.		Day 21 of each period.
Secondary	Predose serum levels of LH and FSH after OC alone and after OC with albiglutide.		Days 1 and 11 through 14 of each period.
Secondary	Predose serum levels of progesterone after OC alone and after OC with albiglutide.		Day 21 of each period.

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
•   Results for study 107032 can be found on the GSK Clinical Study Register.